Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us Donate
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
    All Public Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • KFF Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • Eleven Minutes
    All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • Vaccine Policy in Colorado
  • Family Separation
  • Shakeup at U.S. Preventive Services Task Force
  • Ebola
  • ACA Enrollment

WHAT'S NEW

  • Vaccine Policy in Colorado
  • Family Separation
  • Shakeup at U.S. Preventive Services Task Force
  • Ebola
  • ACA Enrollment

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Wednesday, Feb 25 2015

Full Issue

State Highlights: Pa. House OKs 'Chemo Parity' Bill; Texas Lawmakers Push To Expand Experimental Drug Access

A selection of health policy stories from Pennsylvania, Texas, Delaware, Georgia, California, New Mexico and Iowa.

The Philadelphia Inquirer: 'Chemo Parity' Bill Again Passes Pa. House

Patient and physician groups cheered Monday as the Pennsylvania House overwhelmingly passed legislation to equalize patients' out-of-pocket costs for oral and intravenous cancer drugs. Patients currently may be charged thousands of dollars a month for cancer pills, vs. a $50 co-payment for a dose of a drug given through a vein, because most insurers cover the two formulations in different ways. (McCullough, 2/25)

The Texas Tribune: Lawmakers Push 'Right To Try' Experimental Drugs

It’s kind of like Dallas Buyers Club: A group of sick Texans is seeking to gain access to experimental drugs — only this time, a flurry of state lawmakers is rushing to help them. Eleven of Texas' 31 state senators have put their names on a proposal that would allow terminally ill patients to try investigational drugs that have passed at least the first of three FDA trial phases, once the patient has exhausted other treatment options. There is a similar proposal in the House. (Walters, 2/25)

Stateline: States Strive To Keep Medicaid Patients Out Of ER

Nearly half the states use higher copayments to dissuade Medicaid recipients from unnecessary visits to emergency rooms, where care is more costly. These states require patients to make the payments, which are as high as $30 per visit in Oklahoma, when it is later determined that they did not experience a true medical emergency. (Ollove, 2/24)

The Associated Press: Delaware Legislators Eye Medicaid Budget

Legislative budget writers are continuing their review of budget requests for one of Delaware's biggest government agencies, the Department of Health and Social Services. Wednesday's agenda includes a discussion of the Medicaid and medical assistance programs, which account for more than half of the entire department's budget. (2/25)

Georgia Health News: Bill On Cancer Hospital Takes Immediate Flak

The long-awaited “CTCA bill” has finally arrived – and Georgia’s hospital industry immediately pounced on it in opposition. Legislation that would end major regulatory restrictions on the Cancer Treatment Centers of America’s hospital in Newnan was introduced in the Georgia General Assembly on Tuesday. The lead sponsor is state Rep. Wendell Willard (R-Sandy Springs), chairman of the House Judiciary Committee. (Miller, 2/24)

The Dallas Morning News: Tenet Healthcare Wants To Grow In Texas

Tenet Healthcare Corp. remains bullish on Texas. ... The Dallas-based company, which operates in 16 states, doubled its revenue from Texas in 2013 when it acquired Nashville-based Vanguard Health Systems. Since then, it has steadily added Texas assets. (Jacobson, 2/24)

California Healthline: Scope of Practice Bill Returns, Would Let Nurse Practitioners Prescribe Medication

On Monday, the bill to expand scope-of-practice for nurse practitioners returned to the Legislature with a provision to allow NPs to prescribe medication. (Gorn, 2/24)

Stateline: New Mexico's Nurse Hotline Touted As Model In States

If your infant has a high fever or you’re experiencing an unusual pain in your abdomen and you live in New Mexico, you may want to call the NurseAdvice line before you do anything else. New Mexico is the only state with a 24/7 registered nurse call center that is free to all residents, whether insured or not. In operation since 2006, it has kept tens of thousands of New Mexicans out of emergency rooms and saved the state more than $68 million in health care expenses. (Vestal, 2/25)

The Des Moines Register: CoOportunity Liquidation Approved By Judge

The end is near for CoOportunity Health. Polk County District Judge Arthur Gamble agreed Tuesday to sign an order putting the troubled Iowa-based health-insurer into liquidation as of midnight Saturday. (Leys, 2/24)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Friday, May 22
  • Thursday, May 21
  • Wednesday, May 20
  • Tuesday, May 19
  • Monday, May 18
  • Friday, May 15
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Donate
  • Staff
  • Republish Our Content
  • Contact Us

Follow Us

  • Instagram
  • YouTube
  • LinkedIn
  • Facebook
  • X
  • Bluesky
  • TikTok
  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF